Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1592)	10/5/2007 12:00:40 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

INSM is up 9% after forming a base at the $0.68 level & announcing that it will have a presentation next Wednesday in Frisco at the 2007 BIO Investor Forum bigcharts.marketwatch.com INSM has 4Qs of triple digit improvement on revenues, which also have improved on a sequential basis & it has continued to trim its losses. The EL for 2007 is around $0.20/shr, which is less than half the $0.51/shr in 2006 It seems that the R/R isn't bad at present levels, since if it can get back to test its April 30 H of 1.22 it would be a 54% gain from present levels.<g> bigcharts.marketwatch.com Bernard P.S. April 30 was when it presented positive results from IPLEX PII HIV-Associated adipose redistribution syndrome. RICHMOND, Va., Apr 30, 2007 (BUSINESS WIRE) -- Insmed Inc., (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored clinical study of the company's drug IPLEX(TM) in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS). Preliminary results from the study, being conducted at the University of California, San Francisco, showed that three months of 0.5 mg/kg/day IPLEX treatment in seven patients increased IGF-I levels 3-fold and was associated with significant improvements in fasting glucose levels, the amount of insulin secreted during an oral glucose tolerance test, and overall insulin sensitivity. Moreover, there was a significant reduction in trunk fat and a positive downward trend in waist circumference when compared to baseline. Lipid profiles also tended to improve. Notably, normal glucose tolerance was restored in half of the six patients diagnosed with impaired glucose tolerance (IGT) at the start of the study. These IGT patients also experienced a significant decrease in visceral adipose tissue (VAT). Snip